The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 19, 2019

Filed:

Dec. 02, 2011
Applicants:

Ilia Alexandre Tikhomirov, Toronto, CA;

Maria L. Jaramillo, Beaconsfield, CA;

Maureen D. O'connor-mccourt, Beaconsfield, CA;

Traian Sulea, Kirkland, CA;

Renald Gilbert, Montreal, CA;

Bruno Gaillet, Sainte Julienne, CA;

Jason Baardsnes, Montreal, CA;

Inventors:

Ilia Alexandre Tikhomirov, Toronto, CA;

Maria L. Jaramillo, Beaconsfield, CA;

Maureen D. O'Connor-McCourt, Beaconsfield, CA;

Traian Sulea, Kirkland, CA;

Renald Gilbert, Montreal, CA;

Bruno Gaillet, Sainte Julienne, CA;

Jason Baardsnes, Montreal, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01);
Abstract

An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGYTRYADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVNTAVA (SEQ ID No. 4) CDR2 SASFLYS (SEQ ID No. 5) CDR3 QQHYTTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.


Find Patent Forward Citations

Loading…